KIRhub 2.0
Sign inResearch Use Only

AKT2

Sign in to save this workspace

UniProt P31751 · PDB · AlphaFold · Substrate: Crosstide · Clone: full-length

Top inhibitors

#DrugInhibitionResidualKISSGini
1Capivasertib95.3%4.7%96.480.644
2Netarsudil25.2%74.8%93.220.676
3Midostaurin21.1%78.9%78.640.500
4Sunitinib20.4%79.6%91.730.524
5Ponatinib19.5%80.5%78.230.534
6Acalabrutinib13.2%86.8%99.500.670
7Quizartinib12.8%87.2%99.500.737
8Crizotinib12.5%87.5%91.390.581
9Tepotinib11.5%88.5%99.750.727
10Abemaciclib11.4%88.6%91.480.563
11Vandetanib9.7%90.3%95.740.723
12Pirtobrutinib9.1%90.9%99.490.656
13Neratinib9.0%91.0%93.180.597
14Ibrutinib7.5%92.5%94.740.723
15Vemurafenib7.2%92.8%96.490.598
16Erlotinib7.2%92.8%99.750.695
17Brigatinib7.1%92.9%82.960.513
18Larotrectinib6.0%94.0%99.250.710
19Deucravacitinib5.6%94.4%98.990.718
20Lazertinib5.4%94.6%97.470.674

Paralog block

No paralog group registered for this kinase.

EMT expression

  • Mesenchymal log2(TPM+1): 5.81
  • Epithelial log2(TPM+1): 5.68
  • Fold change: 0.12
  • Status: No significant change

Selectivity landscape vs inhibition on AKT2

Each point is one of the 92 approved drugs; color = inhibition % on AKT2.

Mutation lollipop

Cancer-associated mutations plotted by residue position. Marker size + color scale with the number of distinct cancer reports.

Variants (1)

Mutation × cancer associations

MutationCancerOrganSource
E17Kcarcinoma_lungLungref
E17Kcarcinoma_urinary_tractBladderref
E17Kcarcinoma_breastBreastref
E17Kcarcinoma_thyroidThyroidref
E17Kcarcinoma_upper_aerodigestive_tractBrain/CNSref
E17KBRCA-EUBreastref
E17KBRCA-UKBreastref
E17KLUSC-USLungref
E17KSKCA-BRSkinref
E17KTHCA-USThyroidref
E17KLUSCLungref
E17KTHCAThyroidref

3D structure

Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.

Annotations

Sign in to read and post annotations.

Loading…